SHADDEN BROWN: Open Payments
NPI 1700519683 · SHREVEPORT, LA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$2,002 in 90 payments from 14 companies in 2025. Trend: 2023 $297 · 2024 $1,249 · 2025 $2,002
Food & beverage: $1,995Education: $6
| Company | Payments | Amount |
|---|---|---|
| Alkermes, Inc. | 21 | $455 |
| Vanda Pharmaceuticals Inc. | 12 | $339 |
| Teva Pharmaceuticals USA, Inc. | 7 | $244 |
| ABBVIE INC. | 13 | $208 |
| Otsuka America Pharmaceutical, Inc. | 8 | $171 |
| Janssen Pharmaceuticals, Inc | 6 | $128 |
| Collegium Pharmaceutical, Inc. | 5 | $88 |
| E.R. Squibb & Sons, L.L.C. | 5 | $86 |
| Lundbeck LLC | 3 | $85 |
| Supernus Pharmaceuticals, Inc. | 4 | $73 |
Products named: FANAPT, ARISTADA, AUSTEDO XR, REXULTI, VRAYLAR, LYBALVI, INVEGA SUSTENNA, Jornay PM.
Industry payments across LA — which companies pay providers there.
